Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
exv10w10
 

EXHIBIT 10.10
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
LICENSE AGREEMENT
     THIS AGREEMENT made and entered into this 31st day of March, 2004 (“EFFECTIVE DATE”), by and between DUKE UNIVERSITY, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”), having its principal office at Durham, North Carolina 27708, and Orexigen Therapeutics, Inc., a corporation organized under the laws of Delaware (“OREXIGEN”), with its corporate headquarters and principal office at One Palmer Square, Suite 515, Princeton, NJ 08540.
     WHEREAS, DUKE owns certain DUKE PATENT RIGHTS (as hereinafter defined) relating to the following technology (collectively, the “GADDE/KRISHNAN INVENTIONS”):
    Duke Office of Science and Technology File #2081, entitled “The Combination of Bupropion (Wellbutrintm, Wellbutrin-SRtm, Zybantm) and zonisamide (Zonegramtm) Can Be an Effective Weight Loss and Weight Maintenance Treatment for Obese Patients” and invented by Dr. Kishore Gadde and Dr. Ranga Krishnan (hereinafter, Dr. Gadde and Dr. Krishnan collectively referred to as “INVENTORS”);
 
    Duke Office of Science and Technology File # 2308, entitled “A Method of Reducing Weight Gain Risk Associated with Antidepressant Therapy” and invented by INVENTORS; and
 
    Duke Office of Science and Technology File # 2294, entitled “Zonisamide for Reduction of Weight Gain Risk Associated with Atypical Antipsychotics” and invented by INVENTORS; and
WHEREAS, DUKE has the right to grant licenses under said DUKE PATENT RIGHTS; and
     WHEREAS, OREXIGEN has filed a U.S. provisional patent application entitled [***] (hereinafter the “OREXIGEN PROVISIONAL”); and
     WHEREAS, DUKE possesses certain DUKE DATA (as hereinafter defined) not covered by the DUKE PATENT RIGHTS, but relating to the OREXIGEN PROVISIONAL which OREXIGEN desires to license; and,
     WHEREAS, DUKE desires to have the DUKE PATENT RIGHTS and DUKE DATA developed and commercialized to benefit the public and is willing to grant licenses to each hereunder; and
 
***   Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions .